You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 113 No. 2, February 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correction
 This Article
 •Full text PDF of this Correction
 •Original article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Missing Text

Arch Ophthalmol. 1995;113(2):144.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In the article "Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization," published in the November issue of the ARCHIVES (1994; 112:1471-1475), a line was inadvertently deleted from the first paragraph of the introduction on page 1471. It should have read "In an attempt to inhibit allograft rejection reactions and minimize the potential adverse reactions of conventional treatment with corticosteroids, a variety of potent new immunosuppressive agents, such as cyclosporin, and more recently tacrolimus (FK 506) and rapamycin, have been investigated." The ARCHIVES regrets the error. . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.